Efficacy of three drugs for protecting against gentamicin-induced hair cell and hearing losses

Esperanza Bas Infante, Thomas R Van De Water, C. Gupta, J. Dinh, L. Vu, F. Martínez-Soriano, J. M. Láinez, Jaime Marco Algarra

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

BACKGROUND AND PURPOSE: Exposure to an ototoxic level of an aminoglycoside can result in hearing loss. In this we study investigated the otoprotective efficacy of dexamethasone (DXM), melatonin (MLT) and tacrolimus (TCR) in gentamicin (GM)-treated animals and cultures. EXPERIMENTAL APPROACH: Wistar rats were divided into controls (treated with saline); exposed to GM only (GM); and three GM-exposed groups treated with either DXM, MLT or TCR. Auditory function and cochlear surface preparations were studied. In vitro studies of oxidative stress, pro-inflammatory cytokine mRNA levels, the MAPK pathway and caspase-3 activation were performed in organ of Corti explants from 3-day-old rats. KEY RESULTS: DXM, MLT and TCR decreased levels of reactive oxygen species in GM-exposed explants. The mRNA levels of TNF-α, IL-1βand TNF-receptor type 1 were significantly reduced in GM + DXM and GM + MLT groups. Phospho-p38 MAPK levels decreased in GM + MLT and GM + TCR groups, while JNK phosphorylation was reduced in GM + DXM and GM + MLT groups. Caspase-3 activation decreased in GM + DXM, GM + MLT and GM + TCR groups. These results were consistent with in vivo results. Local treatment of GM-exposed rat cochleae with either DXM, MLT or TCR preserved auditory function and prevented auditory hair cell loss. CONCLUSIONS AND IMPLICATIONS: In organ of Corti explants, GM increased oxidative stress and initiated an inflammatory response that led to the activation of MAPKs and apoptosis of hair cells. The three compounds tested demonstrated otoprotective properties that could be beneficial in the treatment of ototoxicity-induced hearing loss.

Original languageEnglish
Pages (from-to)1888-1904
Number of pages17
JournalBritish Journal of Pharmacology
Volume166
Issue number6
DOIs
StatePublished - Jul 1 2012

Fingerprint

Alopecia
Gentamicins
Hearing Loss
Melatonin
Pharmaceutical Preparations
Dexamethasone
Tacrolimus
Organ of Corti
Cochlea
Caspase 3
Oxidative Stress
Auditory Hair Cells
Messenger RNA
Tumor Necrosis Factor Receptors
Aminoglycosides
p38 Mitogen-Activated Protein Kinases

Keywords

  • ABRs
  • Dexamethasone
  • DPOAEs
  • Gentamicin
  • Laboratory rats
  • Melatonin
  • Otoprotection
  • Ototoxicity
  • Tacrolimus

ASJC Scopus subject areas

  • Pharmacology

Cite this

Bas Infante, E., Van De Water, T. R., Gupta, C., Dinh, J., Vu, L., Martínez-Soriano, F., ... Marco Algarra, J. (2012). Efficacy of three drugs for protecting against gentamicin-induced hair cell and hearing losses. British Journal of Pharmacology, 166(6), 1888-1904. https://doi.org/10.1111/j.1476-5381.2012.01890.x

Efficacy of three drugs for protecting against gentamicin-induced hair cell and hearing losses. / Bas Infante, Esperanza; Van De Water, Thomas R; Gupta, C.; Dinh, J.; Vu, L.; Martínez-Soriano, F.; Láinez, J. M.; Marco Algarra, Jaime.

In: British Journal of Pharmacology, Vol. 166, No. 6, 01.07.2012, p. 1888-1904.

Research output: Contribution to journalArticle

Bas Infante, E, Van De Water, TR, Gupta, C, Dinh, J, Vu, L, Martínez-Soriano, F, Láinez, JM & Marco Algarra, J 2012, 'Efficacy of three drugs for protecting against gentamicin-induced hair cell and hearing losses', British Journal of Pharmacology, vol. 166, no. 6, pp. 1888-1904. https://doi.org/10.1111/j.1476-5381.2012.01890.x
Bas Infante, Esperanza ; Van De Water, Thomas R ; Gupta, C. ; Dinh, J. ; Vu, L. ; Martínez-Soriano, F. ; Láinez, J. M. ; Marco Algarra, Jaime. / Efficacy of three drugs for protecting against gentamicin-induced hair cell and hearing losses. In: British Journal of Pharmacology. 2012 ; Vol. 166, No. 6. pp. 1888-1904.
@article{1b45d8f93a3a4fea9eb2b1af0d6f5a26,
title = "Efficacy of three drugs for protecting against gentamicin-induced hair cell and hearing losses",
abstract = "BACKGROUND AND PURPOSE: Exposure to an ototoxic level of an aminoglycoside can result in hearing loss. In this we study investigated the otoprotective efficacy of dexamethasone (DXM), melatonin (MLT) and tacrolimus (TCR) in gentamicin (GM)-treated animals and cultures. EXPERIMENTAL APPROACH: Wistar rats were divided into controls (treated with saline); exposed to GM only (GM); and three GM-exposed groups treated with either DXM, MLT or TCR. Auditory function and cochlear surface preparations were studied. In vitro studies of oxidative stress, pro-inflammatory cytokine mRNA levels, the MAPK pathway and caspase-3 activation were performed in organ of Corti explants from 3-day-old rats. KEY RESULTS: DXM, MLT and TCR decreased levels of reactive oxygen species in GM-exposed explants. The mRNA levels of TNF-α, IL-1βand TNF-receptor type 1 were significantly reduced in GM + DXM and GM + MLT groups. Phospho-p38 MAPK levels decreased in GM + MLT and GM + TCR groups, while JNK phosphorylation was reduced in GM + DXM and GM + MLT groups. Caspase-3 activation decreased in GM + DXM, GM + MLT and GM + TCR groups. These results were consistent with in vivo results. Local treatment of GM-exposed rat cochleae with either DXM, MLT or TCR preserved auditory function and prevented auditory hair cell loss. CONCLUSIONS AND IMPLICATIONS: In organ of Corti explants, GM increased oxidative stress and initiated an inflammatory response that led to the activation of MAPKs and apoptosis of hair cells. The three compounds tested demonstrated otoprotective properties that could be beneficial in the treatment of ototoxicity-induced hearing loss.",
keywords = "ABRs, Dexamethasone, DPOAEs, Gentamicin, Laboratory rats, Melatonin, Otoprotection, Ototoxicity, Tacrolimus",
author = "{Bas Infante}, Esperanza and {Van De Water}, {Thomas R} and C. Gupta and J. Dinh and L. Vu and F. Mart{\'i}nez-Soriano and L{\'a}inez, {J. M.} and {Marco Algarra}, Jaime",
year = "2012",
month = "7",
day = "1",
doi = "10.1111/j.1476-5381.2012.01890.x",
language = "English",
volume = "166",
pages = "1888--1904",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Efficacy of three drugs for protecting against gentamicin-induced hair cell and hearing losses

AU - Bas Infante, Esperanza

AU - Van De Water, Thomas R

AU - Gupta, C.

AU - Dinh, J.

AU - Vu, L.

AU - Martínez-Soriano, F.

AU - Láinez, J. M.

AU - Marco Algarra, Jaime

PY - 2012/7/1

Y1 - 2012/7/1

N2 - BACKGROUND AND PURPOSE: Exposure to an ototoxic level of an aminoglycoside can result in hearing loss. In this we study investigated the otoprotective efficacy of dexamethasone (DXM), melatonin (MLT) and tacrolimus (TCR) in gentamicin (GM)-treated animals and cultures. EXPERIMENTAL APPROACH: Wistar rats were divided into controls (treated with saline); exposed to GM only (GM); and three GM-exposed groups treated with either DXM, MLT or TCR. Auditory function and cochlear surface preparations were studied. In vitro studies of oxidative stress, pro-inflammatory cytokine mRNA levels, the MAPK pathway and caspase-3 activation were performed in organ of Corti explants from 3-day-old rats. KEY RESULTS: DXM, MLT and TCR decreased levels of reactive oxygen species in GM-exposed explants. The mRNA levels of TNF-α, IL-1βand TNF-receptor type 1 were significantly reduced in GM + DXM and GM + MLT groups. Phospho-p38 MAPK levels decreased in GM + MLT and GM + TCR groups, while JNK phosphorylation was reduced in GM + DXM and GM + MLT groups. Caspase-3 activation decreased in GM + DXM, GM + MLT and GM + TCR groups. These results were consistent with in vivo results. Local treatment of GM-exposed rat cochleae with either DXM, MLT or TCR preserved auditory function and prevented auditory hair cell loss. CONCLUSIONS AND IMPLICATIONS: In organ of Corti explants, GM increased oxidative stress and initiated an inflammatory response that led to the activation of MAPKs and apoptosis of hair cells. The three compounds tested demonstrated otoprotective properties that could be beneficial in the treatment of ototoxicity-induced hearing loss.

AB - BACKGROUND AND PURPOSE: Exposure to an ototoxic level of an aminoglycoside can result in hearing loss. In this we study investigated the otoprotective efficacy of dexamethasone (DXM), melatonin (MLT) and tacrolimus (TCR) in gentamicin (GM)-treated animals and cultures. EXPERIMENTAL APPROACH: Wistar rats were divided into controls (treated with saline); exposed to GM only (GM); and three GM-exposed groups treated with either DXM, MLT or TCR. Auditory function and cochlear surface preparations were studied. In vitro studies of oxidative stress, pro-inflammatory cytokine mRNA levels, the MAPK pathway and caspase-3 activation were performed in organ of Corti explants from 3-day-old rats. KEY RESULTS: DXM, MLT and TCR decreased levels of reactive oxygen species in GM-exposed explants. The mRNA levels of TNF-α, IL-1βand TNF-receptor type 1 were significantly reduced in GM + DXM and GM + MLT groups. Phospho-p38 MAPK levels decreased in GM + MLT and GM + TCR groups, while JNK phosphorylation was reduced in GM + DXM and GM + MLT groups. Caspase-3 activation decreased in GM + DXM, GM + MLT and GM + TCR groups. These results were consistent with in vivo results. Local treatment of GM-exposed rat cochleae with either DXM, MLT or TCR preserved auditory function and prevented auditory hair cell loss. CONCLUSIONS AND IMPLICATIONS: In organ of Corti explants, GM increased oxidative stress and initiated an inflammatory response that led to the activation of MAPKs and apoptosis of hair cells. The three compounds tested demonstrated otoprotective properties that could be beneficial in the treatment of ototoxicity-induced hearing loss.

KW - ABRs

KW - Dexamethasone

KW - DPOAEs

KW - Gentamicin

KW - Laboratory rats

KW - Melatonin

KW - Otoprotection

KW - Ototoxicity

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=84863216852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863216852&partnerID=8YFLogxK

U2 - 10.1111/j.1476-5381.2012.01890.x

DO - 10.1111/j.1476-5381.2012.01890.x

M3 - Article

VL - 166

SP - 1888

EP - 1904

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 6

ER -